Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00031707 · ClinicalTrials.gov registry record · Phase 3

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
429
Enrollment target

NCT00031707 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 429 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00031707, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
429 participants
Enrollment target

Study Summary

RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in treating cancer-related weight loss and loss of appetite. PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty acid-enriched nutritional supplement alone in treating patients who have cancer-related weight loss and lack of appetite.

Interventions

  • OTHER placebo
  • DRUG megestrol acetate
  • DIETARY_SUPPLEMENT eicosapentaenoic acid

Trial Details

FieldValue
Enrollment Target 429 participants
Start Date 2000-03
Est. Completion 2004-01
Phase Phase 3

What the Registry Record Tells You About NCT00031707

The ClinicalTrials.gov registry entry for NCT00031707 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 429 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00031707 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00031707 about?

NCT00031707 is a clinical study titled "Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite". RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in trea...

What is the current status of trial NCT00031707?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2000-03. Estimated completion is 2004-01.

What interventions are being tested in trial NCT00031707?

The interventions under investigation include: placebo (OTHER), megestrol acetate (DRUG), eicosapentaenoic acid (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00031707?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.